Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
| Autor: | Serge Muyldermans, Nick Devoogdt, Yana Dekempeneer, Marleen Keyaerts, Tony Lahoutte, Ahmet Krasniqi, Janik Puttemans, Matthias D'Huyvetter |
|---|---|
| Přispěvatelé: | Faculty of Medicine and Pharmacy, Supporting clinical sciences, Medical Imaging, Department of Bio-engineering Sciences, Translational Imaging Research Alliance |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Clinical Biochemistry Targeted radionuclide therapy targeting vehicles Alpha (ethology) Review 03 medical and health sciences 0302 clinical medicine Neoplasms Drug Discovery medicine Animals Humans Cancer Radioisotopes Pharmacology targeted alpha therapy business.industry Single-Domain Antibodies Alpha Particles medicine.disease nanobody 030104 developmental biology radionuclide labeling 030220 oncology & carcinogenesis Cancer cell Cancer research Pharmaceutical Vehicles Molecular imaging bismuth-213 Nuclear medicine business astatine-211 Astatine |
| Zdroj: | Expert Opinion on Biological Therapy |
| ISSN: | 1744-7682 1471-2598 |
| DOI: | 10.1080/14712598.2016.1185412 |
| Popis: | Introduction: The combination of a targeted biomolecule that specifically defines the target and a radionuclide that delivers a cytotoxic payload offers a specific way to destroy cancer cells. Targeted radionuclide therapy (TRNT) aims to deliver cytotoxic radiation to cancer cells and causes minimal toxicity to surrounding healthy tissues. Recent advances using α-particle radiation emphasizes their potential to generate radiation in a highly localized and toxic manner because of their high level of ionization and short range in tissue. Areas covered: We review the importance of targeted alpha therapy (TAT) and focus on nanobodies as potential beneficial vehicles. In recent years, nanobodies have been evaluated intensively as unique antigen-specific vehicles for molecular imaging and TRNT. Expert opinion: We expect that the efficient targeting capacity and fast clearance of nanobodies offer a high potential for TAT. More particularly, we argue that the nanobodies’ pharmacokinetic properties match perfectly with the interesting decay properties of the short-lived α-particle emitting radionuclides Astatine-211 and Bismuth-213 and offer an interesting treatment option particularly for micrometastatic cancer and residual disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|